Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Hydrocodone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 known ✓ | P41143 | 12/20 | 1.00 |
| ▸ | OPRM1 known ✓ | P35372 | 11/20 | 1.00 |
| ▸ | OPRK1 known ✓ | P41145 | 8/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | MRGPRX2 | Q96LB1 | 1/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrocodone SCHEMBL12638883 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| Hydrocodone SCHEMBL10440385 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| Hydrocodone SCHEMBL2987 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| Hydrocodone SCHEMBL17523150 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| Hydrocodone SCHEMBL101731 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| Hydrocodone SCHEMBL12013631 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| Hydrocodone SCHEMBL6744988 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| Hydrocodone SCHEMBL12402839 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| Hydrocodone SCHEMBL21335350 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| Hydrocodone SCHEMBL12369421 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1LMNAPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019165298-A1 | NOVEL OPIOID COMPOUNDS AND USES THEREOF | RHODES TECHNOLOGIES (US) | 2019-08-29 | — | — | WO | disclosed |
| US-10028945-B2 | Compositions comprising enzyme-cleavable ketone-modified opioid prodrugs and optional inhibitors thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-10028945-B2 | Compositions comprising enzyme-cleavable ketone-modified opioid prodrugs and optional inhibitors thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20170119754-A1 | Compositions Comprising Enzyme-Cleavable Ketone-Modified Opioid Prodrugs and Optional Inhibitors Thereof | 3I, LP | 2017-05-04 | — | — | US | disclosed |
| US-20170119754-A1 | Compositions Comprising Enzyme-Cleavable Ketone-Modified Opioid Prodrugs and Optional Inhibitors Thereof | 3I, LP | 2017-05-04 | — | — | US | disclosed |
| US-9585963-B2 | Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9585963-B2 | Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9493477-B2 | Compositions comprising enzyme-cleavable ketone-modified opioid prodrugs and optional inhibitors thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2016-11-15 | — | — | US | disclosed |
| WO-2016067054-A1 | PROCESSS FOR THE FORMATION OF HYDROCODONE BITATRATE | CAMBREX CHARLES CITY, INC. (US) | 2016-05-06 | — | — | WO | disclosed |
| US-20150297736-A1 | Compositions Comprising Enzyme-Cleavable Opioid Prodrugs and Inhibitors Thereof | 3I, LP | 2015-10-22 | — | — | US | disclosed |
| WO-2011133150-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PRODRUGS OF ACTIVE AGENTS AND INHIBITORS THEREOF | PHARMACOFORE, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011133149-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE OPIOID PRODRUGS AND INHIBITORS THEREOF | PHARMACOFORE, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
| US-20110262355-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE OPIOID PRODRUGS AND INHIBITORS THEREOF | SIGNATURE THERAPEUTICS, INC. | 2011-10-27 | — | — | US | disclosed |
| US-20110262355-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE OPIOID PRODRUGS AND INHIBITORS THEREOF | SIGNATURE THERAPEUTICS, INC. | 2011-10-27 | — | — | US | disclosed |
| WO-2011031350-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE KETONE-MODIFIED OPIOID PRODRUGS AND OPTIONAL INHIBITORS THEREOF | PHARMACOFORE, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
| US-20090036553-A1 | DENDRITIC ENCAPSULATION OF ACTIVE AGENTS | SHIRE LLC (US) | 2009-02-05 | — | — | US | disclosed |
| US-7438900-B2 | Dendritic encapsulation of active agents | SHIRE LLC (US) | 2008-10-21 | — | — | US | disclosed |
| US-20070197451-A1 | Carbohydrate conjugates to prevent abuse of controlled substances | SHIRE LLC | 2007-08-23 | — | — | US | disclosed |
| US-7199129-B2 | Derivatives of morphine-like opioid compounds | MONASH UNIVERSITY (AU) | 2007-04-03 | — | — | US | disclosed |
| US-7199129-B2 | Derivatives of morphine-like opioid compounds | MONASH UNIVERSITY (AU) | 2007-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170119754-A1 | Compositions Comprising Enzyme-Cleavable Ketone-Modified Opioid Prodrugs and Optional Inhibitors Thereof | ACHE, CYP2C18, CYP2C9 | OPRD1 8/4885OPRM1 13/4885OPRK1 4/4885 |
| US-20090036553-A1 | DENDRITIC ENCAPSULATION OF ACTIVE AGENTS | DDOST, CLEC4M, SDCBP | OPRD1 3870/4885OPRM1 3968/4885OPRK1 3429/4885 |
| US-20070197451-A1 | Carbohydrate conjugates to prevent abuse of controlled substances | CES2, FUT6, FUT5 | OPRD1 735/4885OPRM1 124/4885OPRK1 176/4885 |
| US-20110262355-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE OPIOID PRODRUGS AND INHIBITORS THEREOF | ACHE, OPRM1, DNPEP | OPRD1 6/4885OPRM1 2/4885OPRK1 7/4885 |
| US-20150297736-A1 | Compositions Comprising Enzyme-Cleavable Opioid Prodrugs and Inhibitors Thereof | ACHE, OPRM1, DNPEP | OPRD1 6/4885OPRM1 2/4885OPRK1 7/4885 |
| US-10028945-B2 | Compositions comprising enzyme-cleavable ketone-modified opioid prodrugs and optional inhibitors thereof | ACHE, CYP2C18, CYP2C9 | OPRD1 8/4885OPRM1 13/4885OPRK1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.